According to FutureWise's analysis, the humira market in 2025 is US$8.3 billion and is expected to decline to US$3.61 billion by 2033, with a CAGR of -9.88%. The decline is mainly due to the rapid entry of biosimilars after Humira lost exclusivity in major markets. Increased price competition, payer-driven substitution, and more regulatory approvals for Humira biosimilars are shrinking its market share, while healthcare systems push for cost-effective alternatives, further eroding revenues for the branded product.
Humira (adalimumab) is a medication classified as a tumor necrosis factor (TNF) inhibitor, which works by reducing the inflammatory effects of a specific chemical in the body. It is commonly used to treat various inflammatory conditions in adults, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, and hidradenitis suppurativa. In addition to these conditions, Humira is also prescribed for Crohn's disease, juvenile idiopathic arthritis, ulcerative colitis, and uveitis in both adults and children.
As a TNF inhibitor, Humira affects the immune system, potentially reducing its ability to fight off infections. This can increase the likelihood of developing serious infections caused by viruses, fungi, or bacteria. In some cases, these infections can be severe, and there have been reports of fatalities associated with them. One particular infection of concern is tuberculosis (TB), so it is essential for your healthcare provider to test for TB prior to initiating treatment with Humira and to continue monitoring during therapy.
Patients are advised to promptly report any symptoms indicative of infection, such as fever, chills, aches, fatigue, cough, skin sores, diarrhea, or painful urination, either before or during treatment with Humira.
It's important to note that Humira is not recommended for children under the age of 2 (or under 6 years old for Crohn's disease). Prior to starting treatment, children should be current with all recommended childhood vaccinations.
Additionally, there is a noted risk of developing a rare but serious form of lymphoma affecting the liver, spleen, and bone marrow, particularly in adolescents and young men who have Crohn's disease or ulcerative colitis.
FutureWise Market Research has published a report that provides an insightful analysis of Humira Market trends that are affecting the overall market growth.

Request a Free Sample @ https://www.futurewiseresearch.com/contact.aspx?rpt=14214&type=requestsample
Humira Market Segmentation:
By Type
• Humira Syringe
• Humira Pen
By Application
• Ankylosing Spondylitis
• Rheumatoid Arthritis
• Crohn’s Disease
• Others

By Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Competitive Landscape in Humira Market:
• Pfizer
• Amgen
• Novartis AG
• Boehringer Ingelheim
• Mylan N.V.
• AbbVie

Buy now the latest version of this report: https://www.futurewiseresearch.com/checkout.aspx?ReportId=14214&license=multi


**Objectives of this Study: **
1. To provide a comprehensive analysis of the Humira Market By Type, By Application and By Region.
2. To offer detailed insights into factors such as drivers, restraints, trends, and opportunities, as well as segmental and regional influences on market growth.
3. To evaluate current market trends and forecast micro-markets, presenting overall market projections in the form of data sets and PowerPoint presentations.
4. To predict the market size in key regions, including North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of contents as per your requirement
• The customization services offered are free of charge with the purchase of any license of the report.
• You can directly share your requirements/changes to the current table of contents to: [email protected]

FutureWise Research
Contact Person: Vinay Thaploo.
Email: [email protected]
Contact Number: Asia: +91 8605575209 | UK: +44 0113 519 7222
Website: www.futurewiseresearch.com